[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"azoospermia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:azoospermia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,79,102,124,158,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100598632","intelliwell-an-ai-assisted-imaging-platform-for-detection-and-location-of-ultra-rare-testicular-sperm-in-surgical-specimens-100598632",false,"NCT07074015","IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens","IntelliWell: An AI-Assisted Microwell Platform for Label-Free Localization of Ultra-Rare Sperm in Non-Obstructive Azoospermia Micro-TESE Specimens","Inclusion Criteria:\n\n1. Male subjects presenting to Brigham and Women's or Faulkner urology clinic with infertility with clinical non-obstructive azoospermia (clinical diagnosis based on two semen analyses, physical examination, and hormonal testing).\n2. Male subjects undergoing micro-surgical testicular sperm extraction surgery at Brigham and Women's Hospital.\n3. Surgically extracted sperm which are not found to have clinically usable quantities of sperm after standard of care manual processing for which samples would otherwise be discarded and the procedure deemed unsuccessful.\n\nExclusion Criteria:\n\n1\\. Female subject (with whom male subjects intends to conceive with surgically extracted sperm) cannot or will not provide her informed consent for study participation. She will undergo ICSI at BWH with BWH embryology.","MALE","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will help determine whether an AI-assisted microwell platform (IntelliWell) can identify rare sperm cells in testicular samples found to not have sperm by conventional analysis. Instead of discarding testicular tissue which was found to be non-sperm bearing by conventional analysis the testicular tissue will be processed using IntelliWell and, if sperm is found and verified by embryologists, it may be used for intracytoplasmic sperm injection (ICSI).",[26,27],"Infertility","Azoospermia",[29,30,31],"infertility","azoospermia","micro-TESE","RECRUITING","2026-06-17",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2026-04-16",{"date":40,"type":20},"2027-12-01",{"name":42,"class":43},"Brigham and Women's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100620444","identifying-genome-variants-in-non-obstructive-azoospermia-noa-or-primary-ovarian-insufficiency-poi-100620444","NCT07357701","Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)","Identifying Genome Variants and Evaluating PRDM9 and piRNA Clusters as Candidates for Infertility in a Cohort of Individuals With Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Adult male or female, of reproductive age\n4. Clinical diagnosis of NOA, oligospermia, or POI.\n5. In good general health with no medical history suspected as the cause of infertility.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of medications that may cause infertility (chemotherapy, etc.)\n2. Pregnant or lactating\n3. Medical history indicating known common cause of infertility such as karyotype anomalies, Y-chromosome microdeletions, known monogenic causes, or other medical history affecting gamete production (i.e. injuries, surgical operations, infections, radiation, or chemotherapy).","ALL","100 Years",{"count":55,"type":20},500,"OBSERVATIONAL","Background:\n\nInfertility affects 1 in 6 people. Often, the causes of infertility are unknown. Treatments are successful in only about 50% of cases. Infertility caused by non obstructive azoospermia in males and primary ovarian insufficiency in females can have genetic causes. Researchers want to learn more about these genes.\n\nObjective:\n\nTo identify genes that may cause infertility.\n\nEligibility:\n\nAdult men and women with non-obstructive azoospermia (NOA) or primary ovarian insufficiency (POI) of unknown cause.\n\nDesign:\n\nParticipants will provide a saliva sample. A kit will be sent to their home. The kit will contain a collection tube and a cotton swab. They will swirl the swab inside their mouth and then seal it in the tube. They will mail the tube back to the researchers.\n\nMale participants who are having a procedure done to collect tissue from their testes may opt to have leftover tissue provided to study researchers. This tissue would otherwise have been discarded. No new procedures will be performed just for this study.\n\nData may be collected from participants medical records.",[59,27,60],"Primary Ovarian Insufficiency","Oligospermia",[62,63,64,65,30,66,67,59,26],"NOA","POI","Premature Ovarian Insufficiency","oligospermia","diminished ovarian reserve","nonobstructive azoospermia","2026-03-13",{"date":70,"type":36},"2026-03-16",{"date":72,"type":36},"2026-03-11",{"date":74,"type":20},"2031-01-01",{"name":76,"class":77},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":44},"100476095","platelet-rich-plasma-testis-treatment-for-infertile-men-100476095","NCT05479474","Platelet Rich Plasma Testis Treatment for Infertile Men","Platelet Rich Plasma Testis","Inclusion Criteria:\n\n* Men over the age of 18 diagnosed with NOA and at least one failed TESE, negative mapping or negative biopsy\n\nExclusion Criteria:\n\n\\-",{"count":87,"type":20},10,[23],"Investigate the effect of intratesticular injection of autologous platelet rich plasma (PRP) on sperm retrieval rates and IVF outcomes in infertile men who already underwent a negative sperm retrieval. Currently, there is no alternative treatment after failed TESE. Prior series suggest that intratesticular PRP injections may improve TESE outcomes. We hope to determine whether PRP is an effective treatment for this patient population.",[91,92,27],"Male Infertility","Nonobstructive Azoospermia","2026-01-12",{"date":95,"type":36},"2026-01-13",{"date":97,"type":36},"2023-01-18",{"date":99,"type":20},"2026-12-31",{"name":101,"class":43},"Stanford University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":78},"100588478","testicular-evaluation-of-azoospermia-using-micro-ultrasound-100588478","NCT06941922","Testicular Evaluation of Azoospermia Using Micro-Ultrasound","Inclusion criteria:\n\n1. Men with azoospermia confirmed based on semen analysis\n2. Post-vasectomy patients with verified azoospermia after the procedure\n3. Men pre-vasectomy with proven natural fertility or with normal semen analysis\n4. Males assigned at birth over the age of 18\n\nExclusion criteria:\n\n1. History of prior microdissection of the testes\n2. History of hypogonadotropic hypogonadism",true,{"count":110,"type":20},40,"The investigation is a small feasibility study to determine whether there are imaging features related to the seminiferous tubules in the testes under microultrasound. The results from this study will provide guidance on the design and power analysis of future studies in this area.",[27],[114],"azoospermia, infertility, microultrasound, microdissection","2025-07-09",{"date":117,"type":36},"2025-07-11",{"date":119,"type":36},"2025-05-01",{"date":121,"type":20},"2025-12-31",{"name":123,"class":43},"Paul Shin",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":52,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":136,"studyType":56,"phases":4,"briefSummary":137,"conditions":138,"keywords":144,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":156,"locationsCount":44},"100580747","fertility-enhancement-through-regenerative-treatment-in-ovaries-and-testes-100580747","NCT06841328","Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes","Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes: (FERTILE): Prospective Observational Study Evaluating Safety and Efficacy","FERTILE","Male patients:\n\n* Male patients aged 20 to 50 years.\n* Diagnosed with testicular failure (low testosterone) or hypogonadism (impaired gonadal function), or azoospermia (no sperm in ejaculate)\n* Suboptimal response to conventional treatments, such as testosterone replacement therapy (TRT) or fertility-enhancing medications (Clomiphene citrate or anastrozole).\n* General good health without significant contraindications to stem cell or stem cell-derived exosome therapy.\n* Willing and able to provide informed consent and comply with the study protocol.\n* Patients who have been evaluated for testicular failure and are seeking further treatment.\n\nFemale patients:\n\n* Female patients aged 20 to 50 years.\n* Diagnosed with premature ovarian failure (POF) or ovarian insufficiency, confirmed through clinical, hormonal, and imaging assessments.\n* Failure or suboptimal response to conventional treatments, such as hormone therapy.\n* General good health without significant contraindications to stem cell or stem cell-derived exosome therapy.\n* Willing and able to provide informed consent and comply with the study protocol.\n* Patients who have been evaluated for ovarian failure are seeking further treatment.\n\nExclusion criteria\n\n* Severe comorbid conditions, such as advanced cardiovascular disease, renal failure, or uncontrolled diabetes.\n* Active malignancies or history of cancer within the past 5 years.\n* Active infections or systemic inflammatory conditions.\n* History of testicular surgery or trauma that could interfere with the study outcomes.\n* Use of anticoagulants or medications that may contraindicate stem cell or stem cell-derived exosome therapy.\n* Participation in another investigational drug or treatment study within the past 6 months.\n* Contraindications to stem cell or stem cell-derived exosome therapy, such as immune deficiencies or allergies to any treatment components.\n* Severe neurological disorders or cognitive impairment may limit the ability to provide informed consent or follow study instructions.\n* Any condition that, in the investigator's opinion, could interfere with the study or pose an undue risk to the patient.\n* Women with a primary diagnosis of psychogenic ovarian dysfunction or infertility.\n* History of ovarian surgery or trauma that could interfere with the study outcomes.","20 Years","50 Years",{"count":135,"type":20},60,"12 Months","This study investigates the safety and efficacy of stem cell or stem cell-derived exosome therapy for gonadal failure, including testicular failure, hypogonadism, ovarian insufficiency, and premature ovarian failure (POF). Conducted at First IVF Clinic, Dubai, it will include 60 participants (30 males, 30 females) aged 20-50 years who have not responded to conventional treatments such as HRT, TRT, or ART.\n\nParticipants will receive intra-gonadal (testicular or ovarian) injections of stem cells or exosomes, with follow-ups at 3, 6, 9, and 12 months to monitor hormonal changes, gonadal function, and potential adverse effects. The study aims to determine whether regenerative therapy can restore hormone production, enhance reproductive function, and regenerate gonadal tissue, providing a novel, culturally appropriate fertility treatment in the UAE, where donor sperm and eggs are not permitted.\n\nBy bridging the gap between preclinical research and clinical application, this study could offer new hope to individuals with gonadal failure, advancing the field of regenerative reproductive medicine.",[139,140,27,141,142,143],"Gonadal Dysfunction","Gonadal Failure","Testosterone Deficiency","Stem Cells","Hypogonadism, Male",[145,146,147,148,149],"Premature Ovarian Failure","Testicular Failure","low testosterone","Stem cell therapy","Exosomes","2025-04-08",{"date":152,"type":36},"2025-04-10",{"date":150,"type":36},{"date":155,"type":20},"2028-04-30",{"name":157,"class":43},"Jumeirah American Clinic",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100241254","testis-needle-aspiration-of-sperm-in-men-with-azoospermia-100241254","NCT02418832","Testis Needle Aspiration of Sperm in Men With Azoospermia","Rete Testis Needle Aspiration for Retrieval of Sperm in Men With Azoospermia Using Ultrasound Guidance","Inclusion Criteria:\n\n* Men with Obstructive\u002FNon-Obstructive Azoospermia who turned to sperm cell aspiration for IVF and were found suitable for TEFNA and signed consent form.\n\nExclusion Criteria:\n\n* healthy, non-azoospermic men\n* men who are unsuitable for the TEFNA procedure\n* men who don't sign the Informed Consent","16 Years","80 Years",{"count":168,"type":20},150,[23],"Needle aspiration of the epididymis causes rupture and irreversible damage to the duct. Recurring punctures and needle aspirations of fluid and tissue during Testicular Fine Needle Aspiration (TEFNA) procedure cause irreparable injury and loss of part of the testis' tubules. The hypothesis of this research is that production of sperm from the testis will be improved due to ultrasonically guided Rete Testis needle aspiration. In cases of Obstructive Azoospermia, the Rete Testis is expected to contain a large number of sperm cells. In cases of Non-Obstructive Azoospermia, the investigators can expect to produce sperm cells from aspiration of the Rete Testis, which drains all of the testis' tubules. Furthermore, catheterization of the Rete Testis will allow for the drainage of all testes tubules and for the production of sperm cells created locally in some of the tubules or in parts of them.\n\nThe potential advantage of needle aspiration from the Rete Testis is that the procedure will allow for the aspiration from all the testes tubules, as opposed to the standard method of sperm cells production from the testis which samples only some of the tubules. Therefore, it is expected that the procedure suggested in this research will be more efficient than the standard procedures currently in practice. An additional advantage to this procedure is that puncture and aspiration of the tubule network is not expected to block the drainage from the testis, as is the case in aspiration of the epididymis, and it is also not expected to damage the tubules, as is the case in TEFNA and in TESE.",[27],[27,173,174],"Rete Testis","TEFNA","2025-03-02",{"date":177,"type":36},"2025-03-04",{"date":179,"type":36},"2018-07-28",{"date":181,"type":20},"2030-12-31",{"name":183,"class":43},"Hadassah Medical Organization",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":108,"sex":16,"minAge":17,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":193,"conditions":194,"keywords":199,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100487584","the-association-of-gut-microbiota-and-spermatogenic-dysfunction-100487584","NCT05628987","The Association of Gut Microbiota and Spermatogenic Dysfunction","Inclusion Criteria:\n\n* Aged 18 to 45 years, males\n* Body Mass Index (BMI):18.5-29.9 kg\u002Fm\\^2\n* After an abstinence period of 2-7 days, two abnormal semen analysis, the absence of spermatozoa from both replicates will be included in the azoospermia group, the total sperm number (\\\u003C39\\*10\\^6 per ejaculate) or the sperm concentration ( \\\u003C 15 \\* 10\\^6 per ml) will be oligozoospermia group, the progressive motility (PR) (\\\u003C 32%) will be asthenozoospermia group; the percentage of morphologically normal spermatozoa (\\\u003C4%) will be teratozoospermia group\n* Willing to provide feces, urine, blood samples, able to complete study questionnaires aimed at lifestyle factors (cigarette smoking, high temperature environment and others ) and other data collection instruments (e.g. physical activity, food frequency questionnaire, stress and others)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 45 years\n* History of Zocanidin, Vitamin E, antibiotics, clyster, gastrointestinal endoscope in the past 30 days, or other drugs known to interact with semen quality or gut microbiota, history of high alcohol consumption (liquor over 200 ml, beer over 1000 ml) in the past 7 days or drinking every week in the past month\n* A known genetic cause of male factor spermatogenesis dysfunction, including chromosomal or gene disorders (e.g. Y chromosome deletions, CFTR mutation)\n* History of male reproductive system (e.g. testis, epididymis, seminiferous duct and others) damage, surgery, tumor or infection\n* History of Crohn's disease, ulcerative colitis, acute gastrointestinal disease, renal failure, liver cirrhosis, hypoplasia, X-rays exposure and other diseases related to spermatogenic dysfunction, history of intestinal gastrointestinal surgery (exclude appendix surgery)\n* History of psychoses or other mental conditions that would result in cognitive impairment and inability to participate in any part of this study including the informed consent process","45 Years",{"count":192,"type":20},306,"This is a multicenter, case-control study that aims to investigate the relationship between microbiota and sperm quality via stool, blood, and urine microbiome, metabolomics, and collected clinical metadata. The results of the spermatogenic dysfunction, including aspermia, oligozoospermia, asthenozoospermia, and teratozoospermia, will be compared to normal basic semen analysis utilizing the World Health Organization (WHO) semen analysis procedure 5th edition.",[195,27,196,197,198],"Infertility, Male","Oligozoospermia","Asthenozoospermia","Teratozoospermia",[200,195,201],"Microbiota","Sperm","2024-07-22",{"date":204,"type":36},"2024-07-24",{"date":206,"type":36},"2023-02-20",{"date":208,"type":20},"2025-06-30",{"name":210,"class":43},"Zhujiang Hospital",3]